Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
Unmet Needs

Advancing Ocular Drug Delivery

Our combined non-invasive and longer sustained release systems addresses for example, a perceived weakness in the current approach of ocular iontophoresis, a method of driving drugs into and through tissue using a mild electrical current, where Aciont® has significant experience. Iontophoresis works well in driving charged (or ionized) water soluble drugs through transscleral pathways. However, the main problem of this technology relates to the inherent difficulty in retaining a fast clearing, water soluble drug in the eye. While iontophoresis does a great job in accelerating the penetration and increasing the total amount of the drug delivered into eye tissue, it alone does not address the issue of the rapid clearance effects of the eye. Researching iontophoresis, we concluded that “faster and more” isn’t necessarily better when a significant portion of the drug is rapidly cleared from the eye while it is being delivered.

Our previous disclosed research demonstrated that when such therapeutically relevant levels of drug (e.g. 1-2 mgs of prodrug steroid) are delivered into the eye (whether via passive based diffusion alone or via iontophoresis), the pharmacological effects observed under our IVT EIU (endotoxin induced) model are unsatisfactory. However, when the delivery of the drug is accompanied by one of Aciont's novel sustained release formulations the pharmacological effect is improved and the treatment, more efficacious.

'Faster and more' isn’t necessarily better when a significant portion of the drug is rapidly cleared from the eye